Phospholipase A2 pathway in platelets (PLA2 pathway)

Phospholipase A2 enzymes are critical mediators within platelets, catalyzing the hydrolysis at the sn‑2 position of membrane phospholipids to release fatty acids—most notably arachidonic acid—which serves as a precursor for bioactive lipid mediators including thromboxanes and prostaglandins. These lipid mediators play essential roles in promoting platelet aggregation, vascular tone regulation, inflammation, and thrombosis. Multiple isoforms exist within platelets—such as cytosolic cPLA₂α and calcium-independent iPLA₂γ—that respond differentially to agonists like ADP or thrombin by mobilizing distinct pools of membrane lipids. Aberrant activation contributes significantly to cardiovascular diseases through excessive clot formation. While some drugs indirectly modulate this pathway by targeting downstream effectors or regulatory proteins, direct pharmacological inhibition remains largely experimental due to safety concerns related primarily to bleeding risk.[1][3][4] Note: Sulfhydryl group modulation may affect protein function broadly—including that of some enzymes—but is not itself considered a discrete therapeutic target within this context. The canonical therapeutic focus should be on "phospholipase A2" isoforms relevant for platelets rather than any combined entity involving both sulfhydryls and enzymatic pathways.

Other names

Platelet phospholipase A2cPLA2 (cytosolic phospholipase A2)iPLA2γ (calcium-independent phospholipase A2 gamma)PLA₂Platelet arachidonate-releasing enzyme

Inhibition of arachidonic acid release from membrane phospholipids by blocking enzymatic activity; Reduction in synthesis of pro-thrombotic and pro-inflammatory eicosanoids such as thromboxane A₂ and prostaglandins